Drug Information Analysis Service

D'Arcy PF . Triazolam products withdrawn (editorial). Int Pharm J 1991; 5: 246.

Brahams D . Triazolam suspended (letter). Lancet 1991; 338: 938.

Product information. Halcion (triazolam). Kalamazoo, MI: Upjohn, 1992.

Van Der Kroef C . Reactions to triazolam (letter). Lancet 1979; 2: 526.

Rothschild AJ . Disinhibition, amnestic reactions and other adverse reactions secondary to triazolam: A review of the literature. J Clin Psychiatry 1992; 53 (suppl): 69–79.

Oswald I . Triazolam syndrome 10 years on (letter). Lancet 1989; 2: 451.

Bixler EO Kales A Manfredi RL Vgontzas AN Tyson KL Kayles JD . Next-day memory impairment with triazolam use. Lancet 1991; 337: 827–31.

Weingartner HJ Eckardt MJ Hommer DW Mendelson W Wolkowitz OM . Specificity of memory impairments with triazolam use. Lancet 1991; 338: 883–4.

Bixler EO Kales A Manfredi RL Vgontzas AN . Triazolam and memory loss (letter). Lancet 1991; 338: 1391–2.

Wysowski DK Barash D . Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration's Spontaneous Reporting system. Arch Intern Med 1991; 151: 2003–8.

Klett CJ . Review of triazolam data. J Clin Psychiatry 1992; 53 (suppl): 61–7.

Jonas JM Coleman BS Sheridan AQ Kalinske RW . Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychiatry 1992; 53 (suppl): 19–31.

Scharf MB Sachais BA Mayleben DW Fletcher K Jennings SW . A polysomnographic comparison of temazepam 15 and 30 mg with triazolam 0.125 and 0.25 mg in chronic insomnia. Curr Ther Res 1990; 48: 555–67.

O'Donovan MC McGuffin P . Short acting benzodiazepines. BMJ 1993; 306: 945–6.

Hindmarch I Fairweather DB Rombaut N . Adverse events after triazolam substitution (letter). Lancet 1993; 341: 55.

Hawley CJ Walker M Roberts A . Adverse events after triazolam substitution (letter). Lancet 1993; 341: 567.

Vela-Bueno A . Adverse events after triazolam substitution (letter). Lancet 1993; 341: 567.

Jonas JM . Adverse events after triazolam substitution. Lancet 1993; 341: 1150–1.

FDA says ‘Halcion’ is safe. (Media release). Reactions 1992; 403: 3.

Robertson J McD . Cataract prevention: Time for a clinical trial? Br J Clin Pharmacol 1990; 44: 475–6.

Varma SD Richards RD . Ascorbic acid and the eye lens. Ophthalmic Res 1988; 20: 164–73.

Bunce GE Kinoshita J Horwitz J . Nutritional factors in cataract. Annu Rev Nutr 1990; 10: 233–54.

West SK Muqoz B Emmett EA Taylor HR . Cigarette smoking and risk of nuclear cataracts. Arch Ophthalmol 1989; 107: 1166–9.

Varma SD Kumar S Richards RD . Light-induced damage to ocular lens cation pump: Prevention by vitamin C. Proc Natl Acad Sci 1979; 76: 3504–6.

Robertson J McD Donner AP Trevithick JR . A possible role for vitamins C and E in cataract prevention. Am J Clin Nutr 1991; 53 (suppl): 346S–51S.

Urivetzky M Kessaris D Smith AD . Ascorbic acid overdosing: A risk factor for calcium oxalate nephrolithiasis. J Urol 1992; 147: 1215–8.

Varma SD Beachy NA Richards RD . Photoperoxidation of lens lipids: Prevention by vitamin E. Photochem Photobiol 1982; 36: 623–6.

Bendich A Machlin LJ . Safety of oral intake of vitamin E. Am J Clin Nutr 1988; 48: 612–9.

Taylor A . Role of nutrients in delaying cataracts. Ann N Y Acad Sci 1992; 669: 111–24.

Fryer MJ . Evidence for the photoprotective effects of vitamin E. Photochem Photobiol 1993; 58: 304–12.

Bates CJ . Functional significance of micronutrient undernutrition. Proc Nutr Soc 1993; 52: 143–54.

Taylor A . Cataract: Relationships between nutrition and oxidation. J Am Col Nutr 1993; 12: 138–46.

Taylor A Jaques PF Dorey KD . Oxidation and aging: Impact on vision. In: Proceedings of the International Conference on Antioxidants. Princeton, NJ: Princeton Scientific Publications, 1993.

West SK . Who develops cataracts? Arch Ophthalmol 1991; 109: 196–7.

Felson DT . Epidemiology of the rheumatic diseases. In: McCarty DJ Koopman WJ , eds. Arthritis and allied conditions. Philadelphia: Lea & Febiger, 1993: 17–47.

Ellis JM Kishi T Azuma J Folkers K . Vitamin B₆ deficiency in patients with a clinical syndrome including the carpal tunnel defect. Biochemical and clinical response to therapy with pyridoxine. Res Commun Chem Pathol Pharmacol 1976; 13: 743–57.

Ellis JM Azuma J Watanabe T Folkers K Lowell JR Hurst GA , Survey and now data on treatment with pyridoxine of patients having a clinical syndrome including the carpal tunnel and other defects. Res Commun Chem Pathol Pharmacol 1977; 17: 165–77.

Ellis J Folkers K Watanabe T Kaji M Saji S Caldwell JW , Clinical results of a cross-over treatment with pyridoxine and placebo of the carpal tunnel syndrome. Am J Clin Nutr 1979; 32: 2040–6.

Beyer CM Delisa JA Frankel DL Kraft GH . Pyridoxine metabolism in carpal tunnel syndrome with and without peripheral neuropathy. Arch Phys Med Rehabil 1994; 65: 712–6.

Kasdan ML Janes C . Carpal tunnel syndrome and vitamin B₆ . Plast Reconstr Surg 1987; 79: 456–62.

Stransky M Rubin A Lava NS Lazaro RP . Treatment of carpal tunnel syndrome with vitamin B₆: A double blind study. South Med J 1989; 82: 841–2.

Amadio PC . Pyridoxine as an adjunct in the treatment of carpal tunnel syndrome. J Hand Surg 1985; 10A: 237–41.

Smith GP Rudge PJ Peters TJ . Biochemical studies of pyridoxal and pyridoxal phosphate status and therapeutic trial of pyridoxine in patients with carpal tunnel syndrome. Ann Neurol 1984; 15: 104–7.

Berger A Schaumberg HH . More on neuropathy from pyridoxine abuse. N Engl J Med 1984; 311: 986–7.

Schaumburg H Kaplan J Windebank A Vick N Ramus S Pleasure D. , Sensory neuropathy from pyridoxine abuse. N Engl J Med 1983; 309: 445–8.